Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

December 23, 2010
324941
Cancer, Cancer - Prostate
Leslie Howard, MD
Baystate Medical Center, 759 Chestnut St, Springfield, MA
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate cancer.
Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No
Active
Interventional (Clinical Trial), Randomized
2
Dawn DeMarinis
413-794-4362